A NEW weight loss jab that only needs to be taken once monthly leads to “substantial weight loss”, according to early trials.

US biotech major Amgen, a late comer to the growing obesity treatment space, released new data showing that its MariTide ...

Amgen Inc. (NASDAQ:AMGN) is one of the 11 stocks Jim Cramer put under the microscope recently. Cramer highlighted Wall Street ...

A new drug from California-based pharma company Amgen, which has concluded a phase II trial, shows promise as a powerful ...

In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained ...

Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves ...

Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.

The once-monthly drug is still under study but could provide added convenience and another option for patients.

Drugs such as Ozempic (a brand name for semaglutide) are showing promise for weight loss. Another medication in the same ...

A new experimental drug meant to be taken just once a month could lead to “substantial weight reduction” within a year and ...

Alternatives to weekly injections of weight-loss drugs may be on the way. A monthly dose of a new drug called MariTide helped ...

Trial finds weight loss drug taken monthly helps people lose 20% of body weight - The new drug may rival other weight loss ...